Evaluating the validity of animal models for research into therapies for immune-based disorders (Q35795851)

10 August 2017

1 reference

title

Evaluating the validity of animal models for research into therapies for immune-based disorders (English)

1 reference

10 August 2017

Bert A 't Hart

1

1 reference

10 August 2017

Sandra Amor

series ordinal

2

1 reference

10 August 2017

Margreet Jonker

series ordinal

3

1 reference

10 August 2017

language of work or name

1 reference

1 June 2004

1 reference

10 August 2017

1 reference

10 August 2017

9

1 reference

10 August 2017

12

1 reference

10 August 2017

517-524

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Monoclonal antibodies: a powerful new tool in biology and medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Therapy with monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Whole-animal cellular and molecular imaging to accelerate drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Current methods for the generation of human antibodies for the treatment of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Heterologous immunity provides a potent barrier to transplantation tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Tolerance: of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Of mice and not men: differences between mouse and human immunology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Mixed chimerism and tolerance without whole body irradiation in a large animal model

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

The clinical use of antilymphocyte globulin in renal homotransplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

OKT3: First-dose safety and success

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Asymptomatic synovitis precedes clinically manifest arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Non-invasive measurement of brain damage in a primate model of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Gene therapy in nonhuman primate models of human autoimmune disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

1 reference

7 January 2021

Monoclonal antibodies to CD4

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Monoclonal antibody therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Innovative treatment approaches for rheumatoid arthritis. T-cell regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Non-human primate models of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Testing anti-human lymphocyte sera in subhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

The use of monoclonal antibodies to achieve immunological tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Anti-CD4 monoclonal antibody-induced allograft tolerance in rats despite persistence of donor-reactive T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

OKT4 and OKT4A antibody treatment as immunosuppression for kidney transplantation in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Humanized IgG1 and IgG4 anti-CD4 monoclonal antibodies: effects on lymphocytes in the blood, lymph nodes, and renal allografts in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Anti-CD40 therapy extends renal allograft survival in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Prolongation of murine vascularized heart allograft survival by recipient-specific anti-major histocompatibility complex class II antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Anti-CD45RB monoclonal antibody-mediated transplantation tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

The great primate debate

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Treatment with anti-MHC-class-II antibody postpones kidney allograft rejection in primates but increases the risk of CMV activation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

Primate research held to ransom

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903112-5

7 January 2021

10.1016/S1359-6446(04)03112-5

Identifiers

DOI

1 reference

release_6lwa7xab7zce3c5o6zheg43pmu

10 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6lwa7xab7zce3c5o6zheg43pmu

24 November 2022

mapped directly with Wikidata item

1 reference